Lyra TherapeuticsLYRA +14.68%29 Current Ratio is 1.71 as of Dec. 2025, which is 61% below its 10-year median of 4.38. GuruFocus rates LYRA with a GF Score™ of 29/100 and a GF Value™ of $2.54 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, Lyra Therapeutics ranks worse than 73.19% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lyra Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 1.71.
Lyra Therapeutics has a current ratio of 1.71. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lyra Therapeutics's Current Ratio or its related term are showing as below:
LYRA'
s Current Ratio Range Over the Past 10 Years
Min: 1.71 Med: 4.38 Max: 15.54
Current: 1.71
During the past 8 years, Lyra Therapeutics's highest Current Ratio was 15.54. The lowest was 1.71. And the median was 4.38.
LYRA's Current Ratio is ranked worse than 73.19% of 1410
companies
in the Biotechnology industry
Industry Median: 3.9
vs LYRA: 1.71
Lyra Therapeutics (OTCPK:LYRA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lyra Therapeutics Current Ratio Related Terms
Lyra Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Lyra Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LYRA vs EVFM, CLSDQ, ATXI: Current Ratio Comparison
For the Biotechnology subindustry, Lyra Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyra Therapeutics (LYRA) has a Current Ratio of 1.71 as of Dec. 2025. This is 61% below median its historical median of 4.38. Over the past decade, Lyra Therapeutics' Current Ratio has ranged from 1.71 to 15.54. According to the industry distribution chart, Lyra Therapeutics ranks #1032 out of 1410 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Lyra Therapeutics' Current Ratio too high?
Lyra Therapeutics' current Current Ratio of 1.71 is 61% below median its 10-year median of 4.38. Over the past 10 years, this metric has ranged from a low of 1.71 to a high of 15.54. The Biotechnology industry median Current Ratio is 3.90. Lyra Therapeutics' value of 1.71 is 56.2% below this industry median. Based on the distribution chart, Lyra Therapeutics ranks #1032 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lyra Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' Current Ratio compare to EVFM and CLSDQ?
According to the Biotechnology industry distribution chart, Lyra Therapeutics ranks #1032 out of 1410 companies for Current Ratio. This places Lyra Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.90. Lyra Therapeutics' value of 1.71 is 56.2% below this benchmark. Historically, Lyra Therapeutics' own Current Ratio has ranged from 1.71 to 15.54 over the past decade. While the company's 10-year median is 4.38 vs. the industry median of 3.90, Lyra Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyra Therapeutics's current Current Ratio of 1.71 is 56.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyra Therapeutics's current Current Ratio is 1.71, which is 61% below median its own 10-year median of 4.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.54, compared to a current price of $0.71 — trading 72.1% below its estimated fair value. The current Current Ratio is 1.71, which is 61% below median its 10-year median of 4.38 and 56.2% below the Biotechnology industry median of 3.90. Lyra Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current Current Ratio is 1.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyra Therapeutics (LYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued.
The current stock price of $0.71 is trading 72.1% below its estimated GF Value™ of $2.54.
GuruFocus considers Lyra Therapeutics to be Possible Value Trap.
Key valuation signals for LYRA:
Current Ratio: 1.71 (61% below median its 10-year median of 4.38)
GF Value™: $2.54 vs. price of $0.71 (72.1% below fair value)
Industry Position: 56.2% below the Biotechnology median (#1032 of 1410)
No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
29GF Score
Get the complete analysis for LYRA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYRA has been successfully added to your 
